Scarica l'app Stockscreener
0.87
2.35%
0.02
Dyadic International Inc De Borsa (DYAI) Ultime notizie
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress - GlobeNewswire
Dyadic Applied BioSolutions: Strategic Shift and Financial Growth - TipRanks
Dyadic's Strategic Milestone and Capital Raise: A Catalyst for 2026 Commercialization - AInvest
Earnings call transcript: Dyadic Q2 2025 sees revenue growth, stock dips - Investing.com Nigeria
Earnings call transcript: Dyadic Q2 2025 sees revenue growth, stock dips By Investing.com - Investing.com South Africa
DYADIC INTERNATIONAL Earnings Results: $DYAI Reports Quarterly Earnings - Quiver Quantitative
Dyadic Transforms from R&D to Commercial Player with Revenue Surge, Multiple Product Launches Coming - Stock Titan
Global Protein Hydrolysis Enzymes Industry Study: Market Analysis 2025-2035 - MarketReports.us
Will earnings trigger a reversal in Dyadic International Inc.2025 Trade Ideas & Safe Entry Momentum Stock Tips - Newser
Using fundamentals and technicals on KPRXAlgorithmic Prediction of Market Breakouts - Newser
Dyadic International (DYAI) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Should you hold or exit Kilroy Realty Corporation nowShort Term Momentum Based Trading Strategy - Newser
Specialty Enzymes Market to Reach $9.2 Billion by 2029, Driven by Biotech Innovation and Public Funding - GlobeNewswire
Is it time to cut losses on Camtek Ltd.Free Trade Scanner With Buy Zone Alerts - Newser
Dyadic International, Inc. to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13 - Quiver Quantitative
Dyadic International Earnings: Precision Protein Biotech Leader Reports Q2 Results August 13 - Stock Titan
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025 - GlobeNewswire
Dyadic International Closes $5.3 Million Stock Offering - The Globe and Mail
Is Dyadic International Inc. building a consolidation baseFree Trade Timing Strategy With Technical Data - Newser
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock - GlobeNewswire
Dyadic International prices $5.75 million public offering By Investing.com - Investing.com UK
Dyadic International, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock - Quiver Quantitative
Economic Sector Performance Dashboards - Yahoo Finance
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock - GlobeNewswire
Dyadic International prices public offering of 6 million shares - Investing.com Australia
Dyadic International prices public offering of 6 million shares By Investing.com - Investing.com Canada
Dyadic International Raises Capital: 6 Million Share Offering to Fuel Precision Protein Development - Stock Titan
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire
Dyadic International launches public stock offering; shares down 11.5% - MSN
Dyadic International launches public offering of common stock - Investing.com Australia
Dyadic International Announces Strategic Stock Offering: Biotech Platform Expansion Plans Revealed - Stock Titan
What high frequency data says about PRPLDaily Trade Monitor with Pattern Alerts - Newser
How volatile is Dyadic International Inc. stock compared to the marketAchieve rapid portfolio growth with expert guidance - Jammu Links News
Dyadic International receives Nasdaq notice for minimum bid price deficiency - Investing.com
Dyadic International Receives Nasdaq Deficiency Notice - TipRanks
Dyadic International Shifts Focus to Commercial Enterprise - TipRanks
DYAI 8-K: Dyadic Shifts to Commercial Focus With C1 & Dapibus™ Platforms | AIRE SEC FilingForm 8-K - Stock Titan
Dyadic International Receives Nasdaq Deficiency Notice: Compliance Deadline and Potential Delisting - AInvest
Candel Therapeutics Inc. Stock Analysis and ForecastSkyrocketing returns - Jammu Links News
What analysts say about The Real Brokerage Inc. stockOutstanding capital returns - jammulinksnews.com
P 500Short Term Profit Focus - Newser
Why EFC.PRD stock attracts strong analyst attentionStrategic High Profit Opportunities - Newser
Dyadic rebrands as Applied BioSolutions to focus on commercial growth By Investing.com - Investing.com Canada
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions - Yahoo Finance
Dyadic International shareholders approve board proposals at annual meeting - Investing.com
Millennium Management LLC Takes Position in Dyadic International, Inc. (NASDAQ:DYAI) - Defense World
Kopin Co. (NASDAQ:KOPN) Shares Acquired by Bank of America Corp DE - Defense World
Bank of America Corp DE Grows Stock Position in Potbelly Co. (NASDAQ:PBPB) - Defense World
Industrial Enzymes Market worth $12.01 billion by 2030 - MarketsandMarkets
Jane Street Group LLC Has $51,000 Position in Altus Power, Inc. (NYSE:AMPS) - Defense World
Comprehensive Report Reviews the Biotechnology Research Investment Driving Specialty Enzymes Market Growth:... - WhaTech
Top Market Trend Impacting Enzyme Stabilizer Development in the Coming Years: Innovative Oral Enzyme Stabil... - WhaTech
Dyadic International Appoints New President Amid Strategic Shift - TipRanks
Dyadic appoints new president to drive growth - Investing.com Australia
Dyadic's Strategic Transformation: New President to Scale Ancillary Protein Business After Major Partnership Wins - Stock Titan
Protease Market to Projected to Reach USD 5,762.7 Million by 2030, Growing at a CAGR of 5.4% - newstrail.com
Specialty Enzymes Market Top Disruptive Technologies Shaping Industries (2025-2032) - newstrail.com
Dyadic International’s Earnings Call: Progress Amid Challenges - TipRanks
Dyadic International Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Dyadic Q1 2025 revenue misses, stock rises 3.85% - Investing.com Nigeria
Earnings call transcript: Dyadic Q1 2025 revenue misses, stock rises 3.85% By Investing.com - Investing.com South Africa
Dyadic Lands Major CEPI and Gates Foundation Grants as Protein Platform Nears Commercial Launch - Stock Titan
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):